IL-17B Can Impact on Endothelial Cellular Traits Linked to Tumour Angiogenesis | Zendy

Andrew J. Sanders | Zendy; Xiaoxia Guo | Zendy; Malcolm D. Mason | Zendy; Wen G. Jiang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IL-17B Can Impact on Endothelial Cellular Traits Linked to Tumour Angiogenesis

Author(s) -

Andrew J. Sanders,

Xiaoxia Guo,

Malcolm D. Mason,

Wen G. Jiang

Publication year - 2010

Publication title -

journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.228

H-Index - 54

eISSN - 1687-8469

pISSN - 1687-8450

DOI - 10.1155/2010/817375

Subject(s) - angiogenesis , matrigel , medicine , rheumatoid arthritis , cytokine , immunology , cancer research , neovascularization , endothelial stem cell , in vitro , recombinant dna , microbiology and biotechnology , biology , gene , genetics

IL-17B is a member of the IL-17 cytokine family which have been implicated in inflammatory response and autoimmune diseases such as rheumatoid arthritis. The founding member of this family, IL-17 (or IL-17A), has also been implicated in promoting tumour angiogenesis through the induction of other proangiogenic factors. Here we examine the potential of recombinant human IL-17B to contribute to the angiogenic process. In vitro rhIL-17B was able to inhibit HECV endothelial cell-matrix adhesion and cellular migration and also, at higher concentrations, could substantially reduce tubule formation compared to untreated HECV cells in a Matrigel tubule formation assay. This data suggests that IL-17B may act in an antiangiogenic manner.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research